Mark E. Cooper, AO, MB BS, PhD, FRACP, Receives the American Diabetes Association’s 2017 Edwin Bierman Award

Arlington, Virginia
June 2, 2017

Mark E. Cooper, AO, MB BS, PhD, FRACP, has been selected to receive the American Diabetes Association® (Association) 2017 Edwin Bierman Award. This award recognizes a leading scientist who has made outstanding contributions in the field of diabetes-related macrovascular complications and related risk factors. Dr. Cooper will be recognized with this honor during the Association’s 77th Scientific Sessions, June 9-13, 2017, at the San Diego Convention Center. Dr. Cooper will deliver the Edwin Bierman Award Lecture, titled “Metabolic Karma—The Atherogenic Legacy of Diabetes,” on Sunday, June 11.

Currently the Inaugural Head of the Department of Diabetes, Central Clinical School, Monash University and previous Chief Scientific Officer at the Baker Heart and Diabetes Institute, Victoria, Australia, Dr. Cooper is an internationally renowned physician-scientist who has made seminal basic, preclinical and clinical contributions to our understanding and treatment of diabetes-related kidney and macrovascular complications. With more than 500 publications cited more than 40,000 times, Dr. Cooper’s pioneering research has utilized state-of-the-art molecular approaches to identify mechanisms underlying diabetes-accelerated atherosclerosis, to uncover an epigenetic basis for metabolic memory and to determine a role of oxidative stress in diabetes complications.

“Congratulations on this achievement, and thank you for your contributions to our understanding of the macrovascular complications of diabetes,” said Alvin C. Powers, MD, President of Medicine and Science, American Diabetes Association. “Your tremendous body of work, along with the cadre of trainees you’ve prepared for futures in this vital field, have made a lasting impact on our understanding of diabetes and its associated complications.”

In addition to serving in leading roles in many large clinical trials studying type 1 and type 2 diabetes, Dr. Cooper’s contributions include a large network of trainees from around the globe. Many of the fellows, postdoctoral researchers and PhD students Dr. Cooper has trained during the past 25 years have established their own independent careers and leadership positions in diabetes research and practice.

The American Diabetes Association’s 77th Scientific Sessions, to be held June 9-13, 2017, at the San Diego Convention Center, is the world’s largest scientific meeting focused on diabetes research, prevention and care. During the five-day meeting, health care professionals have exclusive access to more than 2,500 original research presentations, participate in provocative and engaging exchanges with leading diabetes experts, and can earn Continuing Medical Education (CME) or Continuing Education (CE) credits for educational sessions. The program is grouped into eight interest areas: Acute and Chronic Complications; Behavioral Medicine, Clinical Nutrition, Education and Exercise; Clinical Diabetes/Therapeutics; Epidemiology/Genetics; Immunology/Transplantation; Insulin Action/Molecular Metabolism; Integrated Physiology/Obesity; and Islet Biology/Insulin Secretion. Brenda Montgomery, RN, MSHS, CDE , President of Health Care and Education ¹, will deliver her address on Saturday, June 10, and Alvin C. Powers, MD, President of Medicine and Science, will present his address on Sunday, June 11. Eight abstracts were selected by the Scientific Sessions Meeting Planning Committee to be presented on Tuesday, June 13, in the President’s Oral Session. These abstracts represent important research being conducted in the field of diabetes today. In total, the 2017 Scientific Sessions includes 378 abstracts in 49 oral sessions; 2,152 poster presentations including 50 moderated poster discussions; and 360 published-only abstracts. Join the Scientific Sessions conversation on Twitter, #2017ADA.

About the American Diabetes Association

Nearly half of American adults have diabetes or prediabetes; more than 30 million adults and children have diabetes; and every 21 seconds, another individual is diagnosed with diabetes in the U.S. Founded in 1940, the American Diabetes Association (ADA) is the nation’s leading voluntary health organization whose mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes. The ADA drives discovery by funding research to treat, manage and prevent all types of diabetes, as well as to search for cures; raises voice to the urgency of the diabetes epidemic; and works to safeguard policies and programs that protect people with diabetes. In addition, the ADA supports people living with diabetes, those at risk of developing diabetes, and the health care professionals who serve them through information and programs that can improve health outcomes and quality of life. For more information, please call the ADA at 1-800-DIABETES (1-800-342-2383) or visit Information from both of these sources is available in English and Spanish. Find us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn)

1 Disclosures for Brenda Montgomery. Employer: AstraZeneca Pharmaceuticals. Montgomery's role as President, Health Care & Education of the American Diabetes Association (Association) is a voluntary position to which she was elected by the members of the Association in 2015. She continues to recuse herself from any and all discussions, decisions or votes that have or could be perceived as having a conflict of interest with her employer.